Market Research Report
Investigation Report on China's Enteral Nutrition Market 2021-2025
|Investigation Report on China's Enteral Nutrition Market 2021-2025|
Published: June 8, 2021
China Research and Intelligence
Content info: 50 Pages
Delivery time: 1-2 business days
Enteral nutrition is mainly used for preoperative feeding of patients with anorexia and related diseases, including mechanical gastrointestinal dysfunction, critical illness and malnutrition. It was developed by Fresenius Kabi and was China in 1995. Chinese market. By 2020, in addition to Niudi Xiya Pharmaceutical (Wuxi) Co.,ltd., there are Fresenius Kabi Deutschland GmbH, Fresenius Kabi Huarui Pharmaceutical Co., Ltd., Abbott Laboratories BV, and Milupa GmnH & Co KG and other 8 manufacturers in China's Enteral Nutrition market.
According to CRI analysis, the sales value of Enteral Nutrition in China has grown steadily year by year from 2016 to 2019. In 2020, due to the impact of the COVID-19 epidemic on the hospital's overall diagnosis and treatment services, the sales value of Enteral Nutrition in China fell slightly, reached CNY1.155 billion in 2020. The CAGR of the sales value of Enteral Nutrition is about 6.5% from 2016 to 2020 in China.
CRI expects that with the effective relief of the COVID-19 epidemic, the sales of Enteral Nutrition in the Chinese market will have a restorative growth from 2021 to 2025. In addition, Enteral Nutrition is widely used clinically. With the improvement and popularization of medical services in China, the demand for Enteral Nutrition will continue to increase, so the sales of Enteral Nutrition in China will maintain a growing trend.